Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma

被引:1
作者
Wen Ming [1 ,2 ]
Xu Weili [4 ]
Ren Lili [3 ]
Gao Fei [6 ,7 ]
Cui Naipeng [2 ]
Wen Junye [1 ]
Li Xinjiang [5 ]
Lin Lin [5 ]
Ma Zhenfeng [2 ]
Chen Baoping [2 ]
Cai Jianhui [6 ,7 ]
机构
[1] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China
[2] Hebei Univ, Dept Surg Oncol, Affiliated Hosp, Baoding 071000, Hebei, Peoples R China
[3] Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding 071000, Hebei, Peoples R China
[4] Hebei Med Univ, Dept Pediat Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China
[5] Hebei Med Univ, Dept Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China
[6] Hebei Med Univ, Teaching & Res Sect, Shijiazhuang 050017, Hebei, Peoples R China
[7] Hebei Gen Hosp, Dept Surg, Dept Oncol & Immunotherapy, Shijiazhuang 050051, Hebei, Peoples R China
关键词
naive T cell; pooled T cells; cytotoxic T lymphocyte; melanoma; immunotherapy; adoptive transfer; IN-VIVO; METASTATIC MELANOMA; ADOPTIVE TRANSFER; DENDRITIC CELLS; PHASE-I; CANCER; MEMORY; LYMPHOCYTES; DETERMINES; REGRESSION;
D O I
10.3760/cma.j.issn.0366-6999.20123364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Adoptive cell transfer (ACT) immunotherapy has been used clinically for years to treat malignancies. Improving the killing efficiency of effector cells, such as tumor-specific cytotoxic T lymphocytes (CTLs), is an important component for enhancing the clinical response of cancer immunotherapy. Hence, we explored a novel method for preparing cancer-specific CTLs using naive T lymphocytes. Methods C57BL/6 mice bearing B16 melanoma tumors were pretreated with cyclophosphamide (CTX) by peritoneal injection. The immunosuppressive influence of CTX on tumor regression and the tumor microenvironment was assessed. Naive T cells and T cell pools were isolated via negative selection using immunomagnetic beads. The proliferative potential and cytokine production of different T cell subpopulations were evaluated in vitro. Tumor-specific CTLs derived from naive T cells (naive CD4+ T cells: naive CD8+ T cells=2:1) and pooled T cells were generated in vitro, respectively. B16 melanoma-bearing C57BL/6 mice were pretreated with CTX, followed by ACT immunotherapy using dendritic cell-induced CTLs. The homing abilities of the effector cells and interleukin-2 (IL-2), interferon-gamma, granzyme B, and perforin mRNA levels in tumor tissues were evaluated, and the change in tumor volume was measured. Results Mice receiving CTX peritoneal pretreatment injections did not display tumor regression compared with control mice. However, a significant downregulation of splenic Tregs and tumor growth factor-beta 1 (TGF-beta 1) and interleukin-10 (IL-10) serum levels was observed (P<0.05). Naive T cells showed a stronger proliferative capacity and elevated cytokine production than did pooled T cells (P<0.05). In addition, effector cells generated from naive T cells displayed more potent antitumor activity in vivo than those derived from pooled T cells (P<0.05). Conclusion Effector cells derived from the naive T cells possess a stronger proliferative potential, homing capacity, and enhanced cytokine production, which leads to a superior antitumor response.
引用
收藏
页码:1328 / 1333
页数:6
相关论文
共 50 条
  • [1] Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice
    Cui Nai-peng
    Xie Shao-jian
    Han Jin-sheng
    Ma Zhen-feng
    Chen Bao-ping
    Cai Jian-hui
    CHINESE MEDICAL JOURNAL, 2012, 125 (05) : 794 - 800
  • [2] Adoptive Transfer of Tumor-Specific Tc17 Effector T Cells Controls the Growth of B16 Melanoma in Mice
    Garcia-Hernandez, Maria de la Luz
    Hamada, Hiromasa
    Reome, Joyce B.
    Misra, Sara K.
    Tighe, Michael P.
    Dutton, Richard W.
    JOURNAL OF IMMUNOLOGY, 2010, 184 (08) : 4215 - 4227
  • [3] Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice
    Tanaka, Kousuke
    Ishikawa, Satoru
    Matsui, Yasunori
    Kawanishi, Takashi
    Tamesada, Makoto
    Harashima, Nanae
    Harada, Mamoru
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (11) : 2143 - 2152
  • [4] Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model
    Contreras, Amanda
    Beems, Megan, V
    Tatar, Andrew J.
    Sen, Siddhartha
    Srinand, Prakrithi
    Suresh, M.
    Luther, Tahra K.
    Cho, Clifford S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [5] Tumor-derived CCL20 affects B16 melanoma growth in mice
    Martin-Garcia, Diego
    Silva-Vilches, Cinthia
    Will, Rainer
    Enk, Alexander H.
    Lonsdorf, Anke S.
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 97 (01) : 57 - 65
  • [6] Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice
    Hu, Zheng
    Xia, Jinxing
    Fan, Wei
    Wargo, Jennifer
    Yang, Yong-Guang
    ONCOTARGET, 2016, 7 (06) : 6448 - 6459
  • [7] Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma
    Watanabe, MAE
    Almeida, DO
    Serrano, SV
    Sales, VSF
    Soares, FA
    DeLucca, FL
    CELLULAR AND MOLECULAR BIOLOGY, 1997, 43 (03) : 393 - 398
  • [8] METASTATIC PHENOTYPE IN HYBRID-CELLS DERIVED FROM B16 MELANOMA
    ITO, M
    IZUHARA, M
    SHIMIZU, K
    SEKIGUCHI, M
    CANCER LETTERS, 1994, 78 (1-3) : 33 - 39
  • [9] Doramectin Induces Apoptosis in B16 Melanoma Cells
    Crotts, Megan S.
    Jacobs, Jena C.
    Baer, Robert W.
    Cox, James L.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2025, 25 (04) : 244 - 256
  • [10] The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
    Fujisawa, Yasuhiro
    Nabekura, Tsukasa
    Nakao, Tomohei
    Nakamura, Yasuhiro
    Takahashi, Takenori
    Kawachi, Yasuhiro
    Otsuka, Fujio
    Onodera, Masafumi
    EXPERIMENTAL DERMATOLOGY, 2009, 18 (04) : 396 - 403